Document:

EXHIBIT 4.27

 

AGREEMENT TO AMEND AND EXTEND

15% CONVERTIBLE DEBENTURE DUE AUGUST
1, 2013

 

THIS AGREEMENT (the “Agreement”)
to amend and extend an existing series A 15% Convertible Debenture due August 1, 2013 (principal amount of $___________) (the “Debenture”)
is made as of September 11, 2013 between American Bio Medica Corporation, a corporation duly organized and existing under the laws
of the State of New York (the “Company”), and ____________________________________, the registered holder (the “Holder”)
of such Debenture. Defined terms not otherwise defined in this Agreement shall have the meanings ascribed in the Debenture. The
Company and the Holder are sometimes referred to collectively in this Agreement as the “Parties” or singly as a “Party.”

 

WHEREAS, the Company desires to extend the
maturity date of the Debenture for either six months or one year, in the option of the Holder (in either case, the “Extended
Maturity Date”); and

 

WHEREAS, the Holder has received and reviewed
an amended a Confidential Memorandum provided by the Company that discloses certain risks and uncertainties related to the extension
of the Maturity Date of the Debenture; and

 

WHEREAS, the Holder is willing to amend
the Debenture to reflect the Extended Maturity Date; and

 

WHEREAS, the Parties agree to amend the
Debenture to extend the maturity date on the terms and conditions set forth in this Agreement.

 

NOW THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1.           Recitals.
The above recitals, definitions, preamble and provisions are hereby made a part of this Agreement.

 

2.           Amendments
to Debenture.

 

(a)          Extended
Maturity Date. The Holder agrees to extend the Maturity Date of the Debenture. The Holder chooses one of the options below by initialing
below:

 

___ (i) extending the Maturity
Date to February 1, 2014, with all other terms and conditions remaining the same;

 

OR,

 

___ (ii) extending the Maturity
Date to August 1, 2014, in which case in addition, the Company will issue to the Holder no later than September 23, 2013 a common
stock purchase warrant (the “Warrant”) to enable the Holder to purchase ________ shares of Company common stock (the
“Warrant Shares”) with an exercise price equal to the average closing sale price of the Company common stock for the
five business days ending September 16, 2013 (the “Exercise Price”), which Warrant will expire August 1, 2015. The
Holder may exercise the Warrant in whole or in part at any time after issuance by paying the Exercise Price in cash or in shares
of Company common stock at the then-current market value.

 

3.           Effective
Date. The Effective Date of this Agreement will be August 1, 2013.

 

    	1

    	 

    

 

4.           No
Waiver. This Agreement shall not be construed as a waiver of any rights of the Holder under the Debenture or a consent to or waiver
or forbearance of any future defaults of the Company of any terms and conditions of the Debenture.

 

5.           Counterparts.
This Agreement may be executed by the Parties in several counterparts, each of which shall be deemed to be an original and all
of which shall constitute together but one and the same agreement. Delivery of executed counterparts of this Agreement electronically
(by email or fax) shall be effective as an original and shall constitute a representation that an original will be delivered.

 

6.           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. Each of the Parties
consents to the jurisdiction of the federal courts whose districts encompass any part of the City of Albany or the state courts
of the State of New York sitting in the City of Albany in connection with any dispute arising under this Agreement and hereby waives,
to the maximum extent permitted by law, any objection, including any objection based on forum non conveniens, to the bringing of
any such proceeding in such jurisdictions.

 

7.           Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

 

8.           No
Other Modification. Except to the extent specifically provided to the contrary in this Agreement, all terms and conditions of the
Debenture shall remain in full force and effect, without modification or limitation. In the event of any conflict or inconsistency
between any Debenture and the provisions of this Agreement, this Agreement will control and supersede to the extent of such conflict
or inconsistency.

 

(Signature page follows)

 

    	2

    	 

    

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to
be duly executed as of the date first above written.

 

AMERICAN BIO MEDICA CORPORATION

 

	By:	 	 	 
	 	Stan Cipkowski	 	 
	 	Chief Executive Officer/Director	 	 
	 	 	 	 
	By:	 	 	 
	 	Melissa A. Waterhouse	 	 
	 	EVP, CCO, SEC	 	 
	 	 	 	 
	THE HOLDER:	 	 
	 	 	 	 
	 	 	 	 
	 	[INSERT NAME]	 	 

 

	Printed Name:	 	 	 

 

	Address:	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

    	3EXHIBIT 4.28

 

NOTE

 

Tinton Falls, New Jersey

 

	$200,000.00	October 7, 2013

 

	 
	 
	 	 

 

1.          Obligation.
For value received and intending to be legally bound, AMERICAN BIO MEDICA CORPORATION, a New York corporation (“Maker”),
hereby promises to pay on or before August 1, 2014 (or earlier as determined below) (the “Due Date”) to the order of
CANTONE ASSET MANAGEMENT LLC (“Payee”), the principal sum of TWO HUNDRED THOUSAND Dollars ($200,000.00), lawful money
of the United States of America together with interest thereon in the amount of fifteen percent (15%) simple interest (the “Rate”),
to be paid in advance as 300,000 restricted shares of ABMC common stock in lieu of payment in cash, accrued from the date August
1, 2013. The principal sum added to any accrued but unpaid interest is referred to herein as the “Amount Due.”

 

a.           Payment
under this Note shall be made in funds immediately available to Payee at its office at 766 Shrewsbury Avenue, Tinton Falls, NJ
07724, or at such other location as the holder of this Note shall designate. In the event the due date of the payment under this
Note is a Saturday, Sunday or legal holiday in the State of New Jersey, such payment shall be due on the next succeeding date which
is not a Saturday, Sunday or such legal holiday, provided that the principal sum shall continue to accrue interest until paid.

 

2.          Prepayment.
Maker may prepay all or any portion of the Amount Due at any time without penalty.

 

3.          Application
of Payments. All payments on this Note shall be applied first to any interest at the Rate and all other sums due hereunder,
and the balance thereof to principal or in such other order as Payee may elect.

 

4.          Default;
Acceleration; Remedies. 

 

a.           Should
there occur any Default (as defined below in Section 5(b), then Payee, at its option and without notice to Maker, may declare immediately
due and payable the entire unpaid balance of the Amount Due by Maker hereunder, together with any interest that may have accrued
thereon at the Rate after the Due Date to the date of Default and thereafter at a rate of interest equal to the highest rate of
interest allowable under the laws of the State of New Jersey (the “Default Rate”), anything herein to the contrary
notwithstanding. Payment thereof may be enforced and recovered in whole or in part at any time by one or more of the remedies provided
Payee in this Note. If Payee employs counsel to enforce this Note by suit or otherwise, Maker will reimburse Payee for all costs
of suit and other expenses in connection therewith, whether or not suit is actually instituted, together with a reasonable attorney’s
fee for collection of Ten Percent (10%) of the total amount then due by Maker to Payee but in no event less than One Thousand Dollars
($1,000.00) together, to the extent permitted by applicable law, with interest on any judgment obtained by Payee at the Default
Rate, including interest at the Default Rate from and after the date of execution, judicial or foreclosure sale until actual payment
is made to Payee of the full amount due Payee.

 

    	 

    	 

    

 

b.           As
used in this Note, “Default” shall occur immediately upon the happening to or by Maker of any of the following events:

 

(1)         Any
default in the payment when due of the Amount Due on the Due Date , or any other sums due, under this Note, which default is not
cured within ten (10) days after written notice;

 

(2)         Any
default in the performance of any of the provisions of this Note, which is not cured within ten (10) days after Maker receives
written notice of that default from Payee;

 

(3)         Any
default in payment of any other indebtedness of the Maker, which default is not cured within thirty (30) days of the date of said
default;

 

(4)         The
making of any misrepresentation to Payee;

 

(5)         The
calling of a meeting of creditors

 

(6)         The
appointment of a committee of creditors;

 

(7)         An
assignment or offer of settlement for the benefit of creditors;

 

(8)         The
voluntary or involuntary application for, or appointment of, a receiver, custodian, guardian, trustee, or other personal representative
for Maker or its property;

 

(9)         The
filing of a voluntary or involuntary petition under the Bankruptcy Code or any similar state statute;

 

(10)        The
occurrence of any other act of insolvency (however expressed or indicated);

 

(11)        The
issuance of a warrant of attachment or for distraint, or the notice of tax lien;

 

(12)        An
entry of judgment;

 

(13)        The
failure to pay, withhold, collect or remit any taxes or tax deficiency when assessed or due, provided however, that so long as
no event of Default shall exist and after giving written notice to Payee, Maker may in good faith contest any such tax and permit
such tax to remain unpaid during the period under any such contest;

 

(14)        The
general failure to pay debts and obligations as the same become due and payable.

 

5.          Remedies
Cumulative, Etc.

 

a.           The
remedies of Payee provided in this Note shall be cumulative and concurrent, may be pursued singly, successively, or together at
the sole discretion of Payee, and may be exercised as often as occasion therefor shall occur; and the failure to exercise any such
right or remedy shall in no event be construed as a waiver or release thereof.

 

    	 

    	 

    

 

b.           The
recovery of any judgment by Payee shall not affect in any manner or to any extent any rights, remedies or powers of Payee under
this Note, but such rights, remedies and powers of Payee shall continue unimpaired as before. The exercise by Payee of its rights
and remedies and the entry of any judgment by Payee shall not adversely affect in any way the interest rate payable hereunder on
any amounts due to Payee but interest shall continue to accrue on such amounts at the rates specified herein.

 

c.           Maker
agrees that any action or proceeding against it to enforce this Note may be commenced in the state courts with jurisdiction in
Monmouth County, New Jersey, or in any federal court with jurisdiction in Monmouth County, New Jersey. Maker also consents to venue
in any federal court having subject matter jurisdiction located in the District of New Jersey. The provisions of this Section shall
not limit or otherwise affect the right of Payee to institute and conduct action in any other appropriate manner, jurisdiction
or court.

 

6.          Additional
Waivers. Maker hereby waives presentment for payment, demand, demand for payment, notice of demand, notice of nonpayment or
dishonor, notice of acceleration, protest and notice of protest of this Note, and all other notices in connection with the delivery,
acceptance, performance, default or enforcement of the payment of the Note. Maker agrees that its liability shall be unconditional
without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time,
renewal, waiver or modification granted or consented to by Payee. Maker consents to any and all extensions of time, renewals, waivers
or modifications that may be granted by Payee with respect to payment or other provisions of this Note.

 

7.          Costs
and Expenses. Maker shall pay upon demand all reasonable costs and expenses incurred by Payee in the exercise of any of its
rights, remedies or powers under this Note and any amount thereof not paid promptly following demand therefor shall be added to
the principal sum hereunder and shall bear interest at the Default Rate from the date of such demand until paid in full.

 

8.          Severability.
If any provision of this Note is held to be invalid or unenforceable by a court of competent jurisdiction, the other provisions
of this Note shall remain in full force and effect and shall be liberally construed in favor of Payee in order to effectuate the
provisions of this Note.

 

9.          Limitation
of Interest to Maximum Lawful Rate. In no event shall the rate of interest payable hereunder exceed the maximum rate of interest
permitted to be charged by applicable law (including choice of law rules) and any interest paid in excess of the permitted rate
shall be refunded to Maker. Such refund shall be made by application of the excessive amount of interest paid against any sums
outstanding under this Note and shall be applied on such order as Payee may determine. If the excessive amount of interest paid
exceeds the sums outstanding under this Note, the portion exceeding the sums outstanding under this Note shall be refunded in cash
by Payee. Any such crediting or refund shall not cure or waive any default by Maker hereunder. Maker agrees, however, that in determining
whether or not any interest payable under this Note exceeds the highest rate permitted by law, any non-principal payment, including
without limitation prepayment fees and late charges, shall be deemed to the extent permitted by law to be an expense, fee, premium
or penalty rather than interest.

 

10.         Limitation
on Payee’s Waivers. Payee shall not be deemed, by any act or omission or commission, to have waived any of its rights
or remedies hereunder unless such waiver is in writing and signed by Payee, and then only to the extent specifically set forth
in the writing. A waiver as to one event shall not be construed as continuing or as a bar to or waiver of any right or remedy to
a subsequent event.

 

    	 

    	 

    

 

11.         No
Offset. The obligations of Maker under this Note shall not be subject to any abatement or offset as a consequence of any claim,
event or transaction otherwise occurring or arising between Maker, Payee and/or any affiliate of any of them, except as Maker and
Payee may otherwise agree.

 

12.         Applicable
Law. This instrument shall be governed by and construed according to the laws of the State of New Jersey.

 

13.         Captions.
The captions or headings of the paragraphs in this Note are for convenience only and shall not control or affect the meaning
or construction of any of the terms or provisions of the Note.

 

14.         Pronouns.
Pronouns used herein shall be deemed to include the masculine, feminine or neuter, singular or plural, as their contexts may
require. The words “Payee” and “Maker” shall be deemed to include the respective heirs, personal representatives,
successors and assigns of Payee and Maker.

 

15.         Construction.
The language in this Agreement shall be construed as a whole according to its fair meaning, strictly neither for nor against
any party, and without implying a presumption that its terms shall be more strictly construed against one party by reason of the
rule of construction that a document is to be construed more strictly against the person who drafted it.

 

16.         Computation.
The unpaid principal amount of this Note, the unpaid interest accrued thereon, the interest rate or rates applicable to such
unpaid principal amount, the duration of such applicability, and all other Amounts Due owing by Maker to Payee pursuant to this
Note shall at all times be ascertained from the records of Payee, which shall be conclusive absent manifest error.

 

17.         Assignment.
This Note may not be assigned or otherwise transferred by Maker without the prior written consent of Payee.

 

18.         Stamp
Taxes. Maker shall pay the cost of any revenue, tax or other stamps now or hereafter required by the laws of the State of New
Jersey (or any of its political subdivisions) or the United States of America to be affixed to this note, and if any taxes are
imposed under the laws of the State of New Jersey (or any of its political subdivisions) or the United States of America with respect
to evidences of indebtedness, Maker shall pay or reimburse Payee upon demand the amount of such taxes without credit against any
indebtedness evidenced by this Note.

 

19.         Notices.
All notices, requests, waivers, demands and other communications hereunder shall be in writing and shall be deemed to have
been duly given, made and received when hand delivered against receipt, or on the day after it is sent by United States certified
or registered mail, postage prepaid, return receipt requested, by nationally recognized overnight courier service, or by fax, to:

 

If to Maker:

 

AMERICAN
BIO MEDICA CORPORATION

122 Smith
Road

Kinderhook,
New York 12106

ATTN: Corporate
Secretary/Chief Compliance Officer

Telephone:
518-758-8158

 

    	 

    	 

    

 

Facsimile:
518-758-8171

Email: mdwaterhouse@abmc.com

 

If to Payee:

 

Cantone Asset Management LLC

766 Shrewsbury
Ave

Tinton Falls,
NJ 07724

Telephone:
732-450-3500

Facsimile:
732-450-3520

Attention: Anthony Cantone

 

or such other address as shall be specified from time to time
(in compliance with the requirements of this Section 20 for the giving of notice) by the parties entitled to receive such notices.

 

IN WITNESS WHEREOF, Maker, intending to
be legally bound hereby, has caused this Note to be duly executed the day and year first above written.

 

	 	MAKER:
	 	 
	 	AMERICAN BIO MEDICA CORPORATION
	 	 
	 	By:	/S/ Melissa A. Waterhouse
	 	 	Melissa A. Waterhouse
	 	 	EVP, Chief Compliance Officer
	 	 	Corporate Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]